Pulmonx Corporation (LUNG) financial statements and ratios from SEC XBRL: revenue $90.50M (TTM), net margin -59.7%, revenue growth 8.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $90.50M |
| Net Margin | -59.7% |
| Revenue Growth (YoY) | 8.0% |
| EPS Growth (YoY) | -7.6% |
| FCF Growth (YoY) | -0.5% |
| Price / Book | 2.13 |
| Price / Sales | 1.10 |
| FCF Yield | -68.5% |
| Altman Z-Score | -4.78 (distress) |
| Piotroski F-Score | 3/9 |
| Sector P/E (Healthcare) | 21.6 |
LUNG overview · LUNG earnings · LUNG KPIs · LUNG investor relations · LUNG ownership · LUNG peers · LUNG filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.